SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Julius Caesar

PatientJulius Caesar
Date of birth1972-07-12
IdentifiersMRN HR-AC001-SYN; SSN (made up) 000-01-6022
Document date2026-10-27
AuthorLucius Fairbanks-Okonkwo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review: seizure control, lipids, blood pressure, and driving. [S]

History of Present Illness

Julius Caesar returns ten weeks after starting levetiracetam, atorvastatin, and aspirin, and six weeks after amlodipine was added. He has had no seizure, spell, or confused awakening, and has missed no doses. He has had slight ankle swelling in the evenings, which he does not mind. His home readings are 118 to 128 over 72 to 80. He has no muscle aches, bleeding, or bruising, and his mood is good. He asks when he can drive again and whether he can stop any of the medicines in time. [S]

ElementDetail
SeizuresNone for ten weeks
Home blood pressure118 to 128 over 72 to 80
Side effectsSlight evening ankle swelling on amlodipine
QuestionsDriving; how long the medicines are needed

Review of Systems

SystemResultFinding
CardiovascularPositiveSlight evening ankle swelling; no chest pain or breathlessness
MusculoskeletalNegativeNo muscle aches
NeurologicalNegativeNo spell or new symptom
PsychiatricNegativeMood good; PHQ-9 3

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Lisinopril 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth each morningOral route2026-08-04activeS
Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily500 mg twice daily, morning and eveningOral route2026-08-18activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtimeOral route2026-08-18activeS
Aspirin 81 mg delayed-release tablet, one tablet by mouth dailyOne tablet by mouth daily with foodOral route2026-08-18activeS
Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for fever or sore throat (no more than 3 g a day)One or two tablets every 6 hours as needed, at most 3 g a day, for up to a weekOral route2026-09-08 to 2026-09-14completedS
Amlodipine 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth each morningOral route2026-09-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-27Body height182cmS
2026-10-27Body weight75kgS
2026-10-27Body mass index (BMI) [Ratio]22.6kg/m2S
2026-10-27Systolic blood pressure124mm[Hg]S
2026-10-27Diastolic blood pressure76mm[Hg]S
2026-10-27Heart rate66/minS
2026-10-27Respiratory rate14/minS
2026-10-27Body temperature36.6CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-27Cholesterol [Mass/volume] in Serum or Plasma136mg/dL<=200 mg/dLNormalS
2026-10-27Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
2026-10-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dL<=129 mg/dLNormalS
2026-10-27Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2026-10-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L7-56 U/LNormalS
2026-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell
CardiovascularRegular rhythm; blood pressure 124/76 mmHg; trace ankle edema
NeurologicalNo focal deficit

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack)resolvedconfirmed R56.9S — Synthetic presenting problem anchored to the documented accounts of falling attacks and fainting fits; it resolves when the cause is found.
Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treatedactiveconfirmed I10S — Synthetic vascular risk factor; no blood pressure from his lifetime is known.
Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dLactiveconfirmed E78.5S — Synthetic vascular risk factor; no lipid value from his lifetime is known.
Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEGactiveconfirmed G40.209S — Synthetic modern diagnosis anchored to the documented falling attacks; the ILAE 2017 seizure types and a structural cause are chosen for teaching and make no claim about what he had.
Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficitactiveconfirmed I69.398S — Synthetic modern finding anchored to the retrospective cerebrovascular hypothesis; it makes no claim about his real brain.
Acute viral upper respiratory infection with low-grade fever and poor sleep, three weeks after starting levetiracetam; rapid COVID-19 and influenza tests negative; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness, chosen to teach cold-remedy choices with hypertension, aspirin, and an antiseizure medicine, and sleep loss as a seizure trigger; it echoes no documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (target below 130/80 mmHg)Every visitCompleted today124/76 mmHg; home 118 to 128 over 72 to 80
LaboratoryLipid panel after starting a statin4 to 12 weeks after starting, then every 3 to 12 monthsCompleted todayLDL 68 mg/dL (target below 70); total cholesterol 136, HDL 46, triglycerides 110 mg/dL
Medication safetyStatin tolerance and liver testsAt the first lipid check, then with symptomsCompleted todayALT 34 U/L; no muscle aches
SurveyDepression screen (PHQ-9)Periodically, at least yearlyCompleted today3; item 9 scored 0
LaboratoryPotassium and creatinineYearly on an ACE inhibitor once stableUp to dateNormal after the start; next in a year
LaboratoryDiabetes screenPeriodically after a stroke without diabetesUp to dateHbA1c 5.6 percent at intake; repeat yearly
Medication safetyInfluenza vaccinationYearlyUp to dateGiven at the preventive visit three weeks ago
SurveyCognitive screen (MoCA)In the first year, then periodicallyUp to date28 of 30 six weeks ago
Medication safetyAntithrombotic adherence and bleedingEvery visitCompleted todayAspirin daily; no bleeding
Medication safetyAntiseizure medicine: seizures, adherence, and side effectsEvery visitCompleted todayNo seizure for ten weeks; no side effects now
ExaminationFall riskEvery visitCompleted todayNo falls
ExaminationWeight and BMIEvery visitCompleted today75.0 kg; BMI 22.6
Self-managementTobacco, alcohol, physical activity, and dietEvery visitCompleted todayDiet and walking kept up; alcohol unchanged; never smoker
Self-managementSeizure safety and drivingEvery visitCompleted todayNot driving; review at six seizure-free months with neurology; riding only with a companion

Goal progress:

Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015); Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018); 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026)

Follow-up: Chronic-care visit in three months; neurology review at six months; lipid panel in six months; next preventive visit in a year. [S]